Synosis: the Financial Leverage of Translational Medicine
This article was originally published in Start Up
Executive Summary
Biotech investors have struggled with the fact that it takes take years, hundreds of millions of dollars, and widely varying sets of expertise to create a product. For Synosis, the answer is translational medicine: it starts life with nine compounds from three European companies, aiming to figure out the best indications and dosing for each, prove them through Phase II, and then out-license them.